Gastrografin

ApprovedSmall molecule

UUniversity of California, Los Angeles

Gastrografin is one of 4 small molecule programs targeting Gastroschisis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroschisisActive, not recruiting

GastroschisisApproved

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Gastroschisis

#DrugCompanyPhaseTrials

Reglan

IIstituto Clinico Humanitas

Approved

—2

Glycerin

CCalm Water Therapeutics LLC

Approved

1 3

Gastrografin

UUniversity of California, Los Angeles

Approved

1 4

Marcaine

IInnocoll

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postoperative Ileus2 trials

Gastrografin in Postoperative Ileus

Completed·UUniversity of Auckland, New Zealand·Phase 2/3·NCT01648972

Study of the Effect of Water Soluble Oral Contrast (Gastrografin) on Postoperative Ileus After Colorectal Surgery

Completed·HHospital Universitari de Bellvitge·Phase 4·NCT01440712·58 enrolled

Adhesive Small Bowel Obstruction1 trial

Optimizing Treatment of Adhesive Small Bowel Obstruction

Recruiting·UUniversity of California, Los Angeles·Phase 3·NCT06182319·40 enrolled

Small Bowel Obstruction1 trial

The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction

Unknown status·JJinling Hospital, China·N/A·NCT03642288·112 enrolled

Bowel Preparation1 trial

Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure

Completed·RRegion Skane·Phase 3·NCT05726097·147 enrolled

Gastroschisis1 trial

The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients.

Withdrawn·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 4·NCT03334578

1 more indication

Low Birth Weight1 trial

Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants

Completed·—·Phase 4·NCT01515696·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Gastrografin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gastrografin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gastrografin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of California, Los Angeles

Gastrografin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postoperative Ileus2 trials

Adhesive Small Bowel Obstruction1 trial

Small Bowel Obstruction1 trial

Bowel Preparation1 trial

Gastroschisis1 trial

Low Birth Weight1 trial

References

Drug Info

Quick Facts

Related News